CAJ | 학술논문

目的：检测食管癌组织BRCA1、β-tubulinⅢmRNA的表达，探讨与紫杉类耐药性的关系。方法：收集36例晚期食管癌组织标本，采用RTq-PCR方法检测组织中BRCA1、β-tubulinⅢmRNA表达，分析二者与紫杉类药物耐药性的关系。结果：BRCA1相对于内参基因β-actin的中位值为6.27；β-tubulinⅢ相对于内参基因β-actin的中位值为4.44。以中位值作为cutoff值，36例标本根据cutoff值分为低表达组和高表达组。BRCA1高表达组的有效率66.7%（12/18）稍高于低表达组55.6%（10/18），但二者差异无统计学意义（P=0.733）。β-tubulinⅢ低表达组的有效率83.3%（15/18）显著高于高表达组38.9%（7/18），差异有统计学意义（P=0.015）。结论：BRCA1 mRNA表达水平与紫杉类药物敏感性差异无统计学意义。β-tubulinⅢmRNA表达水平与紫杉类药物敏感性之间存在相关性。提示β-tubulinⅢ可以作为紫杉烷类药物在晚期食管癌中疗效的预测因子。
목적：검측식관암조직BRCA1、β-tubulinⅢmRNA적표체，탐토여자삼류내약성적관계。방법：수집36례만기식관암조직표본，채용RTq-PCR방법검측조직중BRCA1、β-tubulinⅢmRNA표체，분석이자여자삼류약물내약성적관계。결과：BRCA1상대우내삼기인β-actin적중위치위6.27；β-tubulinⅢ상대우내삼기인β-actin적중위치위4.44。이중위치작위cutoff치，36례표본근거cutoff치분위저표체조화고표체조。BRCA1고표체조적유효솔66.7%（12/18）초고우저표체조55.6%（10/18），단이자차이무통계학의의（P=0.733）。β-tubulinⅢ저표체조적유효솔83.3%（15/18）현저고우고표체조38.9%（7/18），차이유통계학의의（P=0.015）。결론：BRCA1 mRNA표체수평여자삼류약물민감성차이무통계학의의。β-tubulinⅢmRNA표체수평여자삼류약물민감성지간존재상관성。제시β-tubulinⅢ가이작위자삼완류약물재만기식관암중료효적예측인자。
Objective:To investigate the relationship of the mRNA expression of BRCA1 andβ-tubulinⅢwith docetaxel-resistance in esophageal cancer. Methods:The genes BRCA1 andβ-tubulinⅢwere determined at the mRNA level using RT-qPCR in 36 esophageal carcinoma specimens. Results:The mRNA expression of BRCA1 andβ-tubulinⅢwas determined in the 36 tumor samples using RT-qPCR. The median BRCA1 mRNA expression level in relation to that ofβ-actin was 6.27. The medianβ-tubulinⅢmRNA expression level in relation to that ofβ-actin was 4.44. The patients were divided into two groups using these cutoff values. The BRCA1 mRNA expression level was not correlated with the sensitivity of esophageal cancer patients to docetaxel (P=0.733). The response rate of the tumors with highβ-tubulinⅢexpression was (38.9%), which is significantly lower than in patients with lowβ-tubulinⅢexpression (83.3%) (P=0.015). Conclusion:Theβ-tubulinⅢexpression levels in the tumor tissues were probably an important biomarker for the efficacy of docetaxel chemotherapy in esophageal cancer patients. Our study may provide new insights into taxane chemotherapy for advanced esophageal cancer patients.